A 12-month interim analysis of the AGILE Phase III extension study confirms the long-term safety and efficacy of twice-yearly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback